J0491 HCPCS code: Injection, anifrolumab-fnia, 1 mg
J0491 is the HCPCS Level II code for injection, anifrolumab-fnia, 1 mg. In 2024 Medicare paid an average of $12.96 per service for J0491 across 2,980,317 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 300 per day on outpatient hospital claims. Medicare volume rose 290% from 2022 to 2024 (764,908 to 2,980,317 services). In 2024, about 1,131 clinicians billed Medicare for J0491 for 1,507 beneficiaries; Florida, Texas, California accounted for 35% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2022-04-01 |
| Last action effective | 2022-04-01 |
Who bills J0491 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,131 |
| Medicare beneficiaries | 1,507 |
| States with claims | 30 |
| Share of services in top 3 states (Florida, Texas, California) | 35% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J0491, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 764,908 | 622 | $15.19 | $12.11 |
| 2023 | 2,010,019 | 1,130 | $15.43 | $12.29 |
| 2024 | 2,980,317 | 1,507 | $16.28 | $12.96 |
States with the most J0491 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| Florida | 351,908 | $13.08 |
| Texas | 349,236 | $12.60 |
| California | 294,952 | $13.15 |
| New York | 162,904 | $13.00 |
| North Carolina | 158,735 | $13.41 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 300 | Prescribing Information |
| practitioner claims | 300 | Prescribing Information |
What changed for J0491
- 2022-04-01: J0491 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J0491?
J0491 is the HCPCS Level II code for injection, anifrolumab-fnia, 1 mg. Short descriptor: "Inj anifrolumab-fnia 1mg".
How much does Medicare pay for J0491?
In 2024, the average Medicare payment was $12.96 per service (average allowed $16.28).
Does Medicare cover J0491?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J0491 can be billed per day?
300 on outpatient hospital claims; 300 on practitioner claims (NCCI medically unlikely edits).
Related J04 codes
- J0400 — Injection, aripiprazole, intramuscular, 0.25 mg
- J0401 — Injection, aripiprazole (abilify maintena), 1 mg
- J0402 — Injection, aripiprazole (abilify asimtufii), 1 mg
- J0456 — Injection, azithromycin, 500 mg
- J0457 — Injection, aztreonam, 100 mg
- J0458 — Injection, aztreonam/avibactam, 7.5 mg/2.5 mg (10 mg)
- J0461 — Injection, atropine sulfate, 0.01 mg
- J0462 — Injection, atropine sulfate, not therapeutically equivalent to j0461, 0.01 mg
- J0463 — Injection, atropine sulfate (fresenius and therapeutically equivalent), 0.01 mg
- J0470 — Injection, dimercaprol, per 100 mg
- J0475 — Injection, baclofen, 10 mg
- J0476 — Injection, baclofen, 50 mcg for intrathecal trial
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J0491
- Watch J0491 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J0491
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.